State of Alaska Department of Revenue Acquires 25,132 Shares of Enovis Corporation (NYSE:ENOV)

State of Alaska Department of Revenue boosted its position in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 394.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 31,504 shares of the company's stock after buying an additional 25,132 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.06% of Enovis worth $1,203,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Janney Montgomery Scott LLC lifted its stake in shares of Enovis by 6.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 21,782 shares of the company's stock valued at $832,000 after purchasing an additional 1,366 shares during the period. SG Americas Securities LLC grew its holdings in Enovis by 12.0% during the first quarter. SG Americas Securities LLC now owns 19,338 shares of the company's stock valued at $739,000 after purchasing an additional 2,077 shares during the period. Central Valley Advisors LLC acquired a new stake in Enovis in the first quarter worth $1,850,000. GAMMA Investing LLC grew its holdings in shares of Enovis by 144.8% in the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after buying an additional 692 shares during the period. Finally, Farther Finance Advisors LLC raised its stake in Enovis by 266.7% during the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after buying an additional 536 shares during the period. Institutional investors own 98.45% of the company's stock.

Enovis Stock Down 1.5%

NYSE:ENOV traded down $0.48 on Friday, hitting $31.78. 9,300,729 shares of the company's stock were exchanged, compared to its average volume of 883,788. The firm has a 50-day moving average price of $33.06 and a 200-day moving average price of $38.43. Enovis Corporation has a 52 week low of $28.83 and a 52 week high of $49.83. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.55 and a quick ratio of 1.32. The company has a market cap of $1.82 billion, a P/E ratio of 10.27 and a beta of 1.71.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. The firm had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The business's quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.50 EPS. As a group, analysts expect that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of a number of research analyst reports. JMP Securities dropped their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Needham & Company LLC lowered their target price on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Canaccord Genuity Group reduced their price objective on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $58.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.